Pivot Health AI Briefing — May 4, 2026

Show Notes

Hosts: Chris Novak & Maya Johnson In this episode: • Today: biotech IPOs explode back to life, OpenEvidence AI helps crack a complex brain case, and we'll look at how AI is changing the day-to-day for Ve... • Let's start with those IPOs. Chris, biotech has been frozen out of public markets for years. What's happening? • Maya, this is massive. Four biotech companies just raised one and a half billion dollars in IPOs this month—that's the best showing since 2020. Hemab ... • And this matters because biotech funding has been brutal lately. When companies can't go public, they can't fund late-stage trials. That means promisi... • Exactly. I think what's really telling is the upsizing. When companies plan to raise, say, 100 million but end up raising 150 because investors are cl... Subscribe to the newsletter at pivotnews.ai for the full written briefing.

What is Pivot Health — AI News Daily?

Daily AI news for healthcare professionals. Two expert hosts cover how artificial intelligence is changing medicine, diagnostics, drug discovery, and patient care.

Chris Novak: Welcome to Pivot Health! I'm Chris—

Maya Johnson: —and I'm Maya. Let's get into it.

Chris Novak: Today: biotech IPOs explode back to life, OpenEvidence AI helps crack a complex brain case, and we'll look at how AI is changing the day-to-day for Vermont doctors.

Maya Johnson: Let's start with those IPOs. Chris, biotech has been frozen out of public markets for years. What's happening?

Chris Novak: Maya, this is massive. Four biotech companies just raised one and a half billion dollars in IPOs this month—that's the best showing since 2020. Hemab Therapeutics and Seaport Therapeutics both upsized their offerings, which means demand was through the roof.

Maya Johnson: And this matters because biotech funding has been brutal lately. When companies can't go public, they can't fund late-stage trials. That means promising drugs sit on shelves. This surge could unleash a wave of treatments that have been stuck in limbo.

Chris Novak: Exactly. I think what's really telling is the upsizing. When companies plan to raise, say, 100 million but end up raising 150 because investors are clamoring to get in? That's not just a thaw—that's heat returning to the market.

Maya Johnson: Though I'd caution listeners—we've seen false starts before. Remember early 2023? Everyone thought biotech was back, then rates stayed high and everything froze again. The real test is whether this momentum holds through summer.

Chris Novak: Fair point. But Renaissance Capital tracking the highest monthly total in five years? That's not noise, that's signal. If you're in a biotech with solid Phase 2 data, your board is probably dusting off those S-1 filings right now.

Maya Johnson: Speaking of breakthroughs, let's talk about this OpenEvidence case. A patient shows up with one hundred cerebral microhemorrhages—tiny brain bleeds. That's incredibly complex to diagnose.

Chris Novak: Yeah, and here's where it gets interesting. The clinicians used OpenEvidence's AI copilot to help work through the differential diagnosis. This isn't AI replacing doctors—it's AI as a really smart colleague who's read every medical journal ever published.

Maya Johnson: The Cureus report shows exactly how they used it—querying about causes, risk factors, treatment pathways. For something this rare, most doctors might see one case like this in their entire career. But the AI has effectively seen thousands through the literature.

Chris Novak: What strikes me is how naturally it fit into their workflow. They weren't typing prompts into ChatGPT and hoping for the best. OpenEvidence is built specifically for clinical reasoning, with citations and evidence grades.

Maya Johnson: And that's crucial for trust. When you're dealing with brain bleeds, you need to know your AI assistant isn't hallucinating. The fact they published this in a peer-reviewed journal shows real confidence in the tool's reliability.

Chris Novak: I honestly think we'll look back at cases like this as the turning point—when AI went from 'interesting demo' to 'tool I use for my toughest cases.'

Maya Johnson: Now, for the reality check on AI adoption, let's look at Vermont. VTDigger did this deep dive into how AI is actually being used by doctors there, and it's way more nuanced than the hype suggests.

Chris Novak: Right, this is boots-on-the-ground reporting. They found doctors using AI for documentation, prior authorizations, even helping with differential diagnoses. But it's not this sudden revolution—it's gradual integration.

Maya Johnson: What really caught my eye was the burnout angle. Physicians told VTDigger that AI tools are giving them back hours each week. One doctor said they're actually eating dinner with their family again instead of finishing notes until 9 PM.

Chris Novak: That's huge. We talk about AI improving patient outcomes, but physician wellbeing directly impacts care quality. Burned-out doctors make more mistakes, have less empathy, and frankly, they leave medicine entirely.

Maya Johnson: Though the article also highlighted concerns—privacy, over-reliance, the learning curve. Rural Vermont practices don't have IT teams to implement these tools. It's another example of the digital divide in healthcare.

Chris Novak: True, but I'm encouraged that even in rural Vermont, adoption is happening. If AI can work there, it can work anywhere. The key seems to be starting small—maybe just automating chart notes—then building from there.

Maya Johnson: Honestly, that Vermont story might be more important than any flashy announcement. It shows AI becoming boring in the best way—just another tool that makes healthcare work better.

Chris Novak: That's your Pivot Health briefing for May 4, 2026. I'm Chris—

Maya Johnson: —and I'm Maya. See you tomorrow.